Xponance Inc. Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Xponance Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,690 shares of the medical research company’s stock after buying an additional 3,726 shares during the period. Xponance Inc.’s holdings in Amgen were worth $32,169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in shares of Amgen in the third quarter valued at about $26,000. BOK Financial Private Wealth Inc. acquired a new stake in Amgen during the fourth quarter worth about $29,000. OFI Invest Asset Management acquired a new stake in Amgen during the third quarter worth about $26,000. Planned Solutions Inc. acquired a new stake in Amgen during the fourth quarter worth about $30,000. Finally, Providence Capital Advisors LLC acquired a new stake in Amgen during the third quarter worth about $30,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Down 0.5 %

Amgen stock traded down $1.32 during trading on Thursday, reaching $262.75. 1,983,971 shares of the company were exchanged, compared to its average volume of 2,840,891. The stock’s 50 day simple moving average is $277.99 and its two-hundred day simple moving average is $281.37. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market capitalization of $140.81 billion, a P/E ratio of 21.14, a PEG ratio of 2.47 and a beta of 0.58. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm earned $4.09 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.43%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Analyst Ratings Changes

A number of brokerages have issued reports on AMGN. StockNews.com downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. TD Cowen lowered their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. Finally, UBS Group lowered their price target on Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research report on Wednesday. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.